Richard Buchholz - 28 Sep 2021 Form 4 Insider Report for Inspire Medical Systems, Inc. (INSP)

Role
Chief Financial Officer
Signature
/s/ Richard Buchholz
Issuer symbol
INSP
Transactions as of
28 Sep 2021
Net transactions value
+$97,306
Form type
4
Filing time
30 Sep 2021, 16:23:23 UTC
Next filing
15 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INSP Common Stock Options Exercise $67,735 +1,607 +2.8% $42.15* 59,476 28 Sep 2021 Direct F1
transaction INSP Common Stock Options Exercise $29,261 +2,819 +4.7% $10.38* 62,295 28 Sep 2021 Direct
transaction INSP Common Stock Options Exercise $309 +329 +0.53% $0.9400* 62,624 28 Sep 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INSP Stock Option (Right to Buy) Options Exercise $0 -1,607 -14% $0.000000 9,852 28 Sep 2021 Common Stock 1,607 $42.15 Direct F2
transaction INSP Stock Option (Right to Buy) Options Exercise $0 -2,819 -46% $0.000000 3,290 28 Sep 2021 Common Stock 2,819 $10.38 Direct F3
transaction INSP Stock Option (Right to Buy) Options Exercise $0 -329 -100% $0.000000* 0 28 Sep 2021 Common Stock 329 $0.9400 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 80 shares acquired under the Company's 2018 Employee Stock Purchase Plan since the date of the reporting person's last ownership report.
F2 The option vested and became exercisable as to 25% of the original 25,000 underlying shares on December 18, 2019 and has vested or will vest and become exercisable with respect to the remaining 75% of the original underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
F3 The option vested and became exercisable as to 25% of the original 22,556 underlying shares on April 9, 2019 and has vested or will vest and become exercisable with respect to the remaining 75% of the original underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
F4 The option is fully vested and exercisable.